Accustem Sciences Inc (ACUT OTCQB) stock market data APIs
$1.4723
0(0%)
as of September 17, 2025
Try our APIs with
free plan!
Accustem Sciences Inc Financial Data Overview
Price chart is built with
Anychart
AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. It offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. The company also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.
Prev. Close
1.4723
Open
1.4723
High
1.5262
Low
1.4204
52 wk Range
0.2159-2.33
Market Cap
23 626 K
Shares Outstanding
16 072 K
EPS
-0.025
Beta
2.468
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Accustem Sciences Inc data using free add-ons & libraries
Get Accustem Sciences Inc Fundamental Data
Accustem Sciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -1 539 853
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Accustem Sciences Inc News
New
AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th
PHOENIX and LONDON, Sept. 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of can...
AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th
PHOENIX and LONDON, Sept. 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of can...
AccuStem Sciences Chairman Gabriele Cerrone buys additional 8,991 shares
* AccuStem Sciences (OTCQB:ACUT [https://seekingalpha.com/symbol/ACUT]) Friday said [https://seekingalpha.com/pr/20136077-accustem-sciences-inc-announces-chairman-purchase-of-shares] that its Chairm...
AccuStem Sciences, Inc. and EmeritusDX Announce Joint Product Development Agreement and Strategic Partnership
LONDON and PHOENIX, July 17, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, and Emerit...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
